Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 47Carcinoma, Non-Small-Cell Lung 30Pancreatic Neoplasms 24Ovarian Neoplasms 23Fallopian Tube Neoplasms 21Triple Negative Breast Neoplasms 15Breast Neoplasms, Male 14Brenner Tumor 12Melanoma 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Lung Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Adenocarcinoma of Lung 7Urinary Bladder Neoplasms 6Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Stomach Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Cholangiocarcinoma 4Pleural Effusion, Malignant 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Transitional Cell 3Uveal Melanoma 2Tongue Neoplasms 2Thymoma 2

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrent Uterine Corpus Carcinoma × Taxes × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡